Faculties of Medicine and Economics, Institute of Social Medicine and Health Economics, Leipziger Str. 44, 39120, Magdeburg, Germany.
Pharmacoeconomics. 2006 Dec;24 Suppl 2:55-7. doi: 10.2165/00019053-200624002-00006.
In 2001 Germany introduced disease management programmes (DMPs) in order to give sick funds an incentive to improve the treatment of the chronically ill. By 1 March 2005, a total of 3275 programmes had been approved, 2760 for diabetes, 390 for breast cancer and 125 for coronary heart disease, covering roughly 1 million patients. German DMPs show a major fault regarding financial incentives. Sick funds increase their transfers from the risk adjustment scheme when their clients enroll in DMPs. Since this money is a lump sum, sick funds do not necessarily foster treatment of the chronically ill. Similarly, reimbursement of physicians is also not well targeted to the needs of DMPs. Preliminary evidence points to poor performance of German DMPs.
2001 年，德国引入疾病管理计划（DMP），旨在激励医保基金改善慢性病患者的治疗。截至 2005 年 3 月 1 日，共有 3275 个计划获得批准，其中 2760 个用于糖尿病，390 个用于乳腺癌，125 个用于冠心病，覆盖了大约 100 万名患者。德国的 DMP 在经济激励方面存在重大缺陷。当客户参加 DMP 时，医保基金会增加从风险调整计划中转出的资金。由于这笔钱是一笔总额，医保基金不一定会促进慢性病患者的治疗。同样，对医生的报销也没有很好地针对 DMP 的需求。初步证据表明德国 DMP 的表现不佳。
